Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT04535999
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.

Key Dates

Start date
Feb 7, 2022
Status verified
Jul 2025
Primary completion
May 30, 2025
Completion
May 30, 2025

Study Design

Enrollment
16 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open Label
    Secukinumab

Primary Outcome Measure

NAPSI [ Time Frame: Baseline to 24 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Hospital at the University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Hospital at the University of Pennsylvania· Philadelphia, PA

Related Studies